|
|
|||||||
 |
|
|
LinkBack | Thread Tools | Display Modes |
09-23-2010, 10:49 PM
|
|||
|
|||
ZIOPHARM Receives FDA Orphan Drug Designation for Darinaparsin in the Treatment of Pe
NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to darinaparsin (Zinapar™ or ZIO-101) for the treatment of peripheral T-cell Lymphoma (PTCL). The United States Orphan Drug Act of 1983 was created to provide incentives for companies to develop and market treatments for ...
    
|
|
| Thread Tools | |
| Display Modes | |
|
|
Similar Threads
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| FDA grants ZIOPHARM's darinaparsin Orphan Drug Designation for peripheral T-cell Lymp | cancerfr | Non-Hodgkin Lymphoma | 0 | 09-23-2010 10:49 PM |
| Ziopharm Oncology Treatment for T-cell Lymphoma Receives Orphan Drug Designation | cancerfr | Non-Hodgkin Lymphoma | 0 | 09-23-2010 10:49 PM |
| Keryx Biopharmaceuticals Receives Orphan Drug Designation For KRX-0401 (Perifosine) F | cancerfr | Neuroblastoma | 0 | 07-17-2010 09:40 AM |
| ACT Biotech Receives Orphan Drug Designation for Telatinib, an Orally Available and H | cancerfr | Oral Cancer | 0 | 06-03-2010 04:08 PM |
| ACT Biotech Receives Orphan Drug Designation for Telatinib, an Orally Available and H | cancerfr | Oral Cancer | 0 | 06-02-2010 04:30 PM |
Linear Mode
